179 related articles for article (PubMed ID: 37209260)
1. Metastatic differentiated thyroid cancer with negative serum stimulated Tg but positive post-therapeutic
Li X; Li H; Yan Y; Xu H; Wang Y; Liu Y; Gao R
Endocrine; 2023 Oct; 82(1):117-125. PubMed ID: 37209260
[TBL] [Abstract][Full Text] [Related]
2. Value of post-therapeutic ¹³¹I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Luo QY
Endocrine; 2016 Feb; 51(2):283-90. PubMed ID: 26093847
[TBL] [Abstract][Full Text] [Related]
3. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
4. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
5. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of
Gonzalez Carvalho JM; Görlich D; Schober O; Wenning C; Riemann B; Verburg FA; Vrachimis A
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):744-756. PubMed ID: 27909769
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
Danilovic DLS; Coura-Filho GB; Recchia GM; Castroneves LA; Marui S; Buchpiguel CA; Hoff AO; Kopp P
Endocr Relat Cancer; 2022 Aug; 29(8):475-483. PubMed ID: 35613335
[TBL] [Abstract][Full Text] [Related]
10. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
11. Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer.
Zhang Q; Xu W
Nucl Med Commun; 2022 Oct; 43(10):1051-1057. PubMed ID: 35972341
[TBL] [Abstract][Full Text] [Related]
12. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
13. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
[TBL] [Abstract][Full Text] [Related]
14. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
16. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
17. Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a
Spanu A; Nuvoli S; Marongiu A; Gelo I; Mele L; Piras B; Madeddu G
BMC Cancer; 2020 Mar; 20(1):239. PubMed ID: 32197595
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
19. Use of
Wu D; Ylli D; Gomes Lima CJ; Lee W; Burman KD; Wartofsky L; Van Nostrand D
Endocrine; 2018 Oct; 62(1):57-63. PubMed ID: 29797211
[TBL] [Abstract][Full Text] [Related]
20. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
